0001140361-24-024697.txt : 20240507 0001140361-24-024697.hdr.sgml : 20240507 20240507160624 ACCESSION NUMBER: 0001140361-24-024697 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240507 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIGA TECHNOLOGIES INC CENTRAL INDEX KEY: 0001010086 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133864870 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38436 FILM NUMBER: 24921805 BUSINESS ADDRESS: STREET 1: 31 EAST 62ND STREET CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: 212-672-9100 MAIL ADDRESS: STREET 1: 31 EAST 62ND STREET CITY: NEW YORK STATE: NY ZIP: 10065 FORMER COMPANY: FORMER CONFORMED NAME: SIGA PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961108 8-K 1 ef20028413_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 7, 2024

SIGA TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
0-23047
13-3864870
(State or other jurisdiction of incorporation or organization)
(Commission file number)
(I.R.S. employer identification no.)

31 East 62nd Street
New York, New York
  
10065
(Address of principal executive offices)
  
(Zip code)

Registrant’s telephone number, including area code: (212) 672-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
common stock, $.0001 par value
SIGA
The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On May 7, 2024, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024.
 
Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

The full text of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d) The following exhibits are included in this report:

Exhibit
No.
  
Description
     
 
Earning Press Release issued on May 7, 2024.
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
SIGA TECHNOLOGIES, INC.
   
 
By:
/s/ Daniel J. Luckshire
 
Name:
Daniel J. Luckshire
 
Title:
Chief Financial Officer
     
Date: May 7, 2024
    


EX-99.1 2 ef20028413_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
SIGA Reports Financial Results for Three Months Ended March 31, 2024

•      Generated Product Sales of $24 Million and Pre-tax Operating Income of $11 Million
 
•      Corporate Update Conference Call Today at 4:30 PM ET
 
NEW YORK, May 7, 2024 -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2024.
 
“SIGA delivered strong results in the first quarter, with product revenues of $24 million and pre-tax operating income of $11 million, both up over the comparable quarter in 2023,” said Diem Nguyen, Chief Executive Officer. “First quarter financial performance is a testament to our focus on financial and operational excellence, the value of our TPOXX® franchise, and the resilience of our team.  We remain committed to advancing our strategy and enhancing shareholder value as we look forward to progressing our clinical programs, negotiating the next contract with the U.S. Government, and promoting public health.”
 
Summary Financial Results
 
($ in millions, except
per share amounts)
  
Three Months Ended
March 31
  
   
2024
    
2023
  
Product sales(1)
  
$
23.9
    
$
5.7
  
Total revenues
  
$
25.4
    
$
8.3
  
Operating income (loss)(2)
  
$
11.3
    
$ 
(2.1
)
Income (loss) before income taxes(2)
  
$
13.2
    
$ 
(1.2
)
Net income (loss)
  
$
10.3
    
$ 
(0.9
)
Diluted income (loss) per share
  
$
0.14
    
$ 
(0.01
)
(1)
Includes supportive services related to product sales.
 
(2)
Operating income (loss) excludes, and income (loss) before income taxes includes, other income. Both line items exclude the impact of income taxes.
 
Recent Developments:
 
•
On April 11, 2024, the Company’s partner in Japan, Japan Biotechno Pharma, announced that a new drug application for tecovirimat (TPOXX) was filed in Japan for the treatment of smallpox, mpox, cowpox, and complications due to vaccinia virus.
 
•
On April 1, 2024, the Company announced that it entered into an amendment of its international promotion agreement with Meridian Medical Technologies, LLC (Meridian). Effective June 1, 2024, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.  With the amendment, SIGA will have greater control over international promotion activities, which will enable the Company to meet global customers’ needs more effectively during these uncertain times of orthopox threats.
 
•
In first-quarter 2024, SIGA delivered approximately $24 million of oral TPOXX to a diverse mix of customers.  Approximately $16 million of oral TPOXX was delivered to the U.S. government, including $15 million of deliveries to the U.S. Strategic National Stockpile and a $1 million delivery to the U.S. Department of Defense, and approximately $8 million of oral TPOXX was delivered to eight international customers.
 
Capital Management Activity:
 
On March 12, 2024, SIGA’s Board of Directors declared a special cash dividend of $0.60 per share, which was paid on April 11, 2024.
 
Conference Call and Webcast
 
SIGA will host a conference call and webcast to provide a business update today, Tuesday, May 7, 2024, at 4:30 P.M. ET.
 
Participants may access the call by dialing 1-888-886-7786 for domestic callers or 1-416-764-8658 for international callers. A live webcast of the call will also be available on the Company's website at www.siga.com under the 'Events & Presentations' tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
 
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 27772151. The archived webcast will be available in the Events and Presentations section of the Company's website.
 
ABOUT SIGA TECHNOLOGIES, INC.
 
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
 
ABOUT TPOXX®
 
TPOXX is a novel small-molecule drug and the U.S. maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.
 
ABOUT ORTHOPOXVIRUSES
 
Orthopoxvirus, belonging to the family of poxvirus that infect humans, include smallpox, mpox, cowpox and vaccinia. Smallpox, a highly contagious and fatal disease, presents itself as a risk to global health security today given fears of its release accidentally or intentionally as a bioweapon.   Mpox virus, similar to smallpox, causes intermittent human infections, painful lesions, and possible case fatalities. Mpox outbreaks have been observed recently in the US, Europe, and Central & West Africa. Whether through natural occurrence or potential bioweapon warfare, orthopox threatens global health. Anti-virals and vaccines serve as possible solutions to address these threats.
 
FORWARD-LOOKING STATEMENTS
 
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business development and plans including securing new contracts and partnerships. The words or phrases “can be,” “expects,” “may affect,” “may depend,” “believes,” “estimate,” “will”, “project” and similar words and phrases are intended to identify such forward-looking statements. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the 19C BARDA Contract (the “BARDA Contract”), not to exercise all, or any, of the remaining unexercised options under those contracts, (ii) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled at the request or requirement of, or SIGA is not able to enter into a new contract to supply TPOXX to, the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (viii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (ix) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (x) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (xi) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xii) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xiii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, and (xvii) risks associated with responding to an mpox outbreak, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
 
Contacts:
 
Investors
Media
Laine Yonker, EdisonGroup
lyonker@edisongroup.com
Holly Stevens, Berry & Company
hstevens@berrypr.com

SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
As of

   
March 31, 2024
    
December 31, 2023
  
ASSETS
            
Current assets
            
Cash and cash equivalents
  
$
143,868,648
    
$
150,145,844
  
Accounts receivable
    
18,127,180
      
21,130,951
  
Inventory
    
63,721,788
      
64,218,337
  
Prepaid expenses and other current assets
    
2,174,993
      
3,496,028
  
Total current assets
    
227,892,609
      
238,991,160
  
                 
Property, plant and equipment, net
    
1,193,237
      
1,331,708
  
Deferred tax asset, net
    
11,011,668
      
11,048,118
  
Goodwill
    
898,334
      
898,334
  
Other assets
    
2,149,482
      
2,083,535
  
Total assets
  
$
243,145,330
    
$
254,352,855
  
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities
                
Accounts payable
  
$
2,523,350
    
$
1,456,316
  
Accrued expenses and other current liabilities
    
6,122,929
      
10,181,810
  
Dividend payable
    
42,673,509
      
—
  
Deferred IV TPOXX® revenue
    
20,788,720
      
20,788,720
  
Income tax payable
    
2,703,690
      
21,690,899
  
Total current liabilities
    
74,812,198
      
54,117,745
  
                 
Other liabilities
    
3,342,927
      
3,376,203
  
Total liabilities
    
78,155,125
      
57,493,948
  
Commitments and contingencies
                
Stockholders’ equity
                
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,122,516 and 71,091,616, issued and outstanding at March 31, 2024 and December 31, 2023, respectively)
    
7,112
      
7,109
  
Additional paid-in capital
    
236,766,447
      
235,795,420
  
Accumulated deficit
    
(71,783,354
)
    
(38,943,622
)
Total stockholders’ equity
    
164,990,205
      
196,858,907
  
Total liabilities and stockholders’ equity
  
$
243,145,330
    
$
254,352,855
  

SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME/(LOSS) (UNAUDITED)

   
Three Months Ended
March 31,
  
   
2024
    
2023
  
Revenues
            
Product sales and supportive services
  
$
23,878,677
    
$
5,702,515
  
Research and development
    
1,551,178
      
2,620,510
  
Total revenues
    
25,429,855
      
8,323,025
  
                 
Operating expenses
                
Cost of sales and supportive services
    
3,225,314
      
1,150,187
  
Selling, general and administrative
    
7,875,773
      
4,235,108
  
Research and development
    
3,053,369
      
5,046,036
  
Total operating expenses
    
14,154,456
      
10,431,331
  
Operating income/(loss)
    
11,275,399
      
(2,108,306
)
Other income, net
    
1,942,437
      
890,629
  
Income/(loss) before income taxes
    
13,217,836
      
(1,217,677
)
(Provision)/benefit for income taxes
    
(2,940,496
)
    
299,422
  
Net and comprehensive income/(loss)
  
$
10,277,340
    
$
(918,255
)
Basic income/(loss) per share
  
$
0.14
    
$
(0.01
)
Diluted income/(loss) per share
  
$
0.14
    
$
(0.01
)
Weighted average shares outstanding: basic
    
71,093,653
      
72,197,038
  
Weighted average shares outstanding: diluted
    
71,562,996
      
72,197,038
  


EX-101.SCH 3 siga-20240507.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 siga-20240507_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 siga-20240507_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 07, 2024
Entity File Number 0-23047
Entity Registrant Name SIGA TECHNOLOGIES, INC.
Entity Central Index Key 0001010086
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3864870
Entity Address, Address Line One 31 East 62nd Street
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10065
City Area Code 212
Local Phone Number 672-9100
Title of 12(b) Security common stock, $.0001 par value
Trading Symbol SIGA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://siga.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20028413_8k.htm siga-20240507.xsd siga-20240507_lab.xml siga-20240507_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20028413_8k.htm": { "nsprefix": "siga", "nsuri": "http://siga.com/20240507", "dts": { "inline": { "local": [ "ef20028413_8k.htm" ] }, "schema": { "local": [ "siga-20240507.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "siga-20240507_lab.xml" ] }, "presentationLink": { "local": [ "siga-20240507_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://siga.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240507to20240507", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028413_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240507to20240507", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028413_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://siga.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-24-024697-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-024697-xbrl.zip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end XML 17 ef20028413_8k_htm.xml IDEA: XBRL DOCUMENT 0001010086 2024-05-07 2024-05-07 false 0001010086 8-K 2024-05-07 SIGA TECHNOLOGIES, INC. DE 0-23047 13-3864870 31 East 62nd Street New York NY 10065 212 672-9100 false false false false common stock, $.0001 par value SIGA NASDAQ false